Literature DB >> 29436146

Natural history and genotype-phenotype correlations in 72 individuals with SATB2-associated syndrome.

Yuri A Zarate1, Constance L Smith-Hicks2, Carol Greene3, Mary-Alice Abbott4, Victoria M Siu5, Amy R U L Calhoun6, Arti Pandya7, Chumei Li8, Elizabeth A Sellars1, Julie Kaylor9, Katherine Bosanko1, Louisa Kalsner10, Alice Basinger11, Anne M Slavotinek12, Hazel Perry12, Margarita Saenz13, Marta Szybowska8, Louise C Wilson14, Ajith Kumar14, Caroline Brain15, Meena Balasubramanian16, Holly Dubbs17, Xilma R Ortiz-Gonzalez17, Elaine Zackai17, Quinn Stein18, Cynthia M Powell7, Samantha Schrier Vergano19, Allison Britt20, Angela Sun21,22, Wendy Smith23, E Martina Bebin24, Jonathan Picker25, Amelia Kirby26, Hailey Pinz26, Hannah Bombei6, Sonal Mahida2, Julie S Cohen2, Ali Fatemi2, Hilary J Vernon2, Rebecca McClellan2, Leah R Fleming27, Brittney Knyszek27, Michelle Steinraths28, Cruz Velasco Gonzalez29, Anita E Beck21,22, Katie L Golden-Grant22, Alena Egense3, Aditi Parikh30,31,32, Chantalle Raimondi33, Brad Angle33, William Allen34, Suzanna Schott34, Adi Algrabli35, Nathaniel H Robin36, Joseph W Ray20, David B Everman37, Michael J Gambello38, Wendy K Chung39.   

Abstract

SATB2-associated syndrome (SAS) is an autosomal dominant disorder characterized by significant neurodevelopmental disabilities with limited to absent speech, behavioral issues, and craniofacial anomalies. Previous studies have largely been restricted to case reports and small series without in-depth phenotypic characterization or genotype-phenotype correlations. Seventy two study participants were identified as part of the SAS clinical registry. Individuals with a molecularly confirmed diagnosis of SAS were referred after clinical diagnostic testing. In this series we present the most comprehensive phenotypic and genotypic characterization of SAS to date, including prevalence of each clinical feature, neurodevelopmental milestones, and when available, patient management. We confirm that the most distinctive features are neurodevelopmental delay with invariably severely limited speech, abnormalities of the palate (cleft or high-arched), dental anomalies (crowding, macrodontia, abnormal shape), and behavioral issues with or without bone or brain anomalies. This comprehensive clinical characterization will help clinicians with the diagnosis, counseling and management of SAS and help provide families with anticipatory guidance.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  2q33.1; SATB; SATB2-associated syndrome; facial recognition technology; genotype-phenotype correlation; natural history

Mesh:

Substances:

Year:  2018        PMID: 29436146     DOI: 10.1002/ajmg.a.38630

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  20 in total

1.  Evaluation of Face2Gene using facial images of patients with congenital dysmorphic syndromes recruited in Japan.

Authors:  Hiroyuki Mishima; Hisato Suzuki; Michiko Doi; Mutsuko Miyazaki; Satoshi Watanabe; Tadashi Matsumoto; Kanako Morifuji; Hiroyuki Moriuchi; Koh-Ichiro Yoshiura; Tatsuro Kondoh; Kenjiro Kosaki
Journal:  J Hum Genet       Date:  2019-05-29       Impact factor: 3.172

2.  Satb2 regulates proliferation and nuclear integrity of pre-osteoblasts.

Authors:  Todd Dowrey; Evelyn E Schwager; Julieann Duong; Fjodor Merkuri; Yuri A Zarate; Jennifer L Fish
Journal:  Bone       Date:  2019-07-17       Impact factor: 4.398

3.  Differentiation of MISSLA and Fanconi anaemia by computer-aided image analysis and presentation of two novel MISSLA siblings.

Authors:  Magdalena Danyel; Zhuo Cheng; Christine Jung; Felix Boschann; Jean Tori Pantel; Nurulhuda Hajjir; Ricarda Flöttmann; Solveig Schulz; Ilja Demuth; Eamonn Sheridan; Stefan Mundlos; Denise Horn; Martin A Mensah
Journal:  Eur J Hum Genet       Date:  2019-07-18       Impact factor: 4.246

4.  The facial dysmorphology analysis technology in intellectual disability syndromes related to defects in the histones modifiers.

Authors:  Giulia Pascolini; Nicole Fleischer; Alessandro Ferraris; Silvia Majore; Paola Grammatico
Journal:  J Hum Genet       Date:  2019-05-13       Impact factor: 3.172

5.  Dental radiographic findings in 18 individuals with SATB2-associated syndrome.

Authors:  John Scott; Chad Adams; Kirt Simmons; Andrea Feather; John Jones; Larry Hartzell; Lucia Wesley; Adam Johnson; Jennifer Fish; Katherine Bosanko; Stephen Beetstra; Yuri A Zarate
Journal:  Clin Oral Investig       Date:  2018-10-12       Impact factor: 3.573

6.  Spatiotemporal MicroRNA-Gene Expression Network Related to Orofacial Clefts.

Authors:  F Yan; L M Simon; A Suzuki; C Iwaya; P Jia; J Iwata; Z Zhao
Journal:  J Dent Res       Date:  2022-06-30       Impact factor: 8.924

7.  Individuals with SATB2-associated syndrome with and without autism have a recognizable metabolic profile and distinctive cellular energy metabolism alterations.

Authors:  Yuri A Zarate; Jenny-Li Örsell; Katherine Bosanko; Sujata Srikanth; Lauren Cascio; Rini Pauly; Luigi Boccuto
Journal:  Metab Brain Dis       Date:  2021-03-04       Impact factor: 3.584

8.  Experiences with offering pro bono medical genetics services in the West Indies: Benefits to patients, physicians, and the community.

Authors:  Andrew K Sobering; Dong Li; Jennifer S Beighley; John C Carey; Tyhiesia Donald; Sarah H Elsea; Karla P Figueroa; Jennifer Gerdts; Andre Hamlet; Ghayda M Mirzaa; Beverly Nelson; Stefan M Pulst; Janice L Smith; Flora Tassone; Helga V Toriello; Ruth H Walker; Katherine R Yearwood; Elizabeth J Bhoj
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-12-04       Impact factor: 3.908

Review 9.  Protein ensembles link genotype to phenotype.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  PLoS Comput Biol       Date:  2019-06-20       Impact factor: 4.475

10.  Genes encoding SATB2-interacting proteins in adult cerebral cortex contribute to human cognitive ability.

Authors:  Isabella Cera; Laura Whitton; Gary Donohoe; Derek W Morris; Georg Dechant; Galina Apostolova
Journal:  PLoS Genet       Date:  2019-02-06       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.